WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 7, 862-872. Review Article ISSN 2277–7105

COMPREHENSIVE ASSESSMENT AND EVALUATION OF "ENHANCING PRODUCT QUALITY AND PROCESS EFFICIENCY THROUGH QUALITY BY DESIGN"

Sayan Mahapatra* and B. Babu

Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS Academy Of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India.

Article Received on 13 Feb. 2024,
Revised on 05 March 2024,
Accepted on 26 March 2024
DOI: 10.20959/wjpr20247-31859

***Corresponding Author**
Sayan Mahapatra
Department of Pharmaceutical Analysis, JSS College of Pharmacy, JSS Academy Of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India.

ABSTRACT

Quality By Design (QbD), a strategic strategy that attempts to improve product processes and quality across several industries, has become quite popular. Scientific concepts, risk management, and quality control are all part of this well-organized framework for the whole product lifecycle. Manufacturers may produce products that are secure, efficient, and dependable by employing QbD to concentrate on the critical factors that affect product quality. This article meticulously examines and analyses the adoption of QbD, along with its advantages, difficulties, and potential outcomes. At every stage of the product lifecycle, a methodical approach known as Quality by Design (QbD) includes risk management, with an emphasis on its benefits, challenges, and potential. The approach for evaluating the influence and adoption of the principles makes use of survey data and experimental findings. A methodical Design of Experiment (DoE) approach is used to extensively assess the influence of various process factors on the acknowledged key quality attributes (CQAs) of the finished tablet. A case study is also included to demonstrate the usefulness of the recommended technique. Results and Advantages at XYZ Biopharma, batch failure and product variability were significantly reduced.

KEYWORDS: Key process parameters, Process analytical technology, Design space, Failure mode, and effect analysis.

INTRODUCTION

In several sectors, Quality by Design (QBD) has evolved into a systematic framework for improving the effectiveness of processes and product quality.[1] This article goes into considerable detail regarding the advantages, difficulties, and likely outcomes of QbD. The approach to evaluating the impact and adoption of QbD principles uses survey data and experimental findings.[2] Organizations may proactively ensure product quality, reduce variability, and build process resilience by utilizing QbD. Understanding and managing crucial elements that affect product quality is a top focus for QbD.[3] Manufacturers create a design space that describes the variety of input variables and process parameters, preserving continuous product quality, by establishing key quality attributes (CQAs) and essential process parameters (CPPs). Quality assurance is greatly improved by real-time process monitoring and control, which is made possible by process analytical technology (PAT) and modern analytical techniques. Despite all the advantages of QbD, its implementation might be difficult because of problems with cross-disciplinary cooperation, data management, and regulatory compliance.[4] Organizations may, however, overcome these difficulties by spending money on personnel, supplies, and training. In many sectors, Quality by Design (QbD) has become an essential strategy for improving the effectiveness of procedures and the caliber of output.[5] It improves a methodical framework that incorporates risk management, scientific concepts, and quality control at every stage of the product life cycle. Manufacturers may supply consumers with products that are safe, efficient, and dependable by focusing on comprehending and managing the critical factors that affect quality.[6] This essay extensively examines and evaluates the use of QbD principles with an emphasis on its benefits, challenges, and potential. Recent years have seen a rise in the acceptance of QbD's advantages, particularly in sectors like food production, chemical processing and pharmaceutical manufacturing.[7] The traditional trial-and- error method of product design and production is been replaced with a science-based strategy that promotes it through an understanding of product characteristics and process parameters.[8] As a result of this paradigm change, the process may become more predictable, variability, might be reduced, and productive quality assurance might be used. Quality attributes (CQAs) and key process parameters (CPPs) must first be determined via a comprehensive understanding of the product and process in order to adopt QbD principles.[9] These elements serve as the foundation for building the design space, together with knowledge of the underlying systems and associated hazards.[10] The range of input variables and process parameters that the product can dependably achieve the requisite quality features are specified by the design space. It offers flexibility for process optimization, ensuring that changes to raw materials, machinery, and environmental elements may be made without lowering the quality of the finished product. Manufacturers may decrease the need for post-approval revisions and lower regulatory risks by concentrating on design space.[11] Through the use of process analytical technology (PAT), state-of-the-art analytical techniques, and quality control systems, QbD also emphasizes the necessity of real-time process monitoring and management.[12] In order to maintain product quality with the design parameters, manufacturers may use these technologies to continuously analyze process performance, identify deviations, and make data-driven choices. Even though implementing QbD has numerous advantages, firms could run into problems. Data management, legal compliance, and interdisciplinary collaboration are a few of them. To develop the essential competencies inside the company, QbD also necessitates an investment in resources, technology, and training.[13]

METHODOLOGY

It is possible to combine survey and experimental methodologies to evaluate how well Quality by Design (QbD) ideas are been used. An overview of the methodology for assessing the implementation and impact of QbD in a particular organization or industry is provided in the following section.[14]

- **Sample Survey:** Create a well-organized survey that includes crucial questions on the use of QbD, including how well it is understood, accepted, and integrated into the production of goods. Include inquiries on selecting critical quality attributes (CQAs), selecting critical process parameters (CPPs), using process analytical technology (PAT), design space, and selecting critical process parameters (CPPs).[15] Include inquiries about the perceived advantages, difficulties, and obstacles related to the use of QbD.[16] To guarantee the validity and caliber of the data collected, make sure the survey has been vetted and pilot-tested. A representative group of business specialists, including process engineers, quality assurance staff, and management stakeholders, should receive the survey.[17]
- **Data collection:** Use the proper techniques, such as in-person interviews or online surveys, to gather survey results. To promote truthful and accurate responses, make sure confidentiality and anonymity are maintained. To learn more about the use of QbD in-depth, consider including open-ended questions.[18]

- **Data analysis:** In order to ascertain the extent of QbD acceptability, spot trends and gauge public opinion on QbD implementation, statistical methods should be employed to analyze the survey data. To synthesize the quantitative data and offer significant insides, use descriptive statistics. Find themes, problems, and success stories that are relevant to quality by design by qualitatively analyzing the open-ended replies.[19] To determine the effect of QbD on certain product qualities or process factors, design and carry out studies. Create control and experimental groups to compare QbD-based procedures with traditional approaches. Choose which particular process or quality aspect will be the test's main emphasis.[20] Consider the design space, do a risk analysis, and continue to monitor the experimental group by applying the QbD principles. Measure the experiment's outcomes and evaluate the findings by concentrating on the effectiveness of the QbD technique with the standard approach. Analyze how QbD impacts outcomes such as product quality, process effectiveness, and other crucial factors.[21]
- **Integration of Survey and Experimental Data:** Compare the survey findings with the experimental data to get a complete picture of the current state of QbD implementation and its effects. Establish links between the level of QbD adoption and the observed experiment findings. Consider how the experimental results address the functions discussed in the survey's difficulties section.[22] Draw judgments on the benefits, constraints, and areas for improvement in the implementation of QbD based on the combined data.[23]
- **Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs) Identification:** A detailed understanding of the product and its intended quality features is the first step in the QbD process. CQAs are acknowledged as the crucial characteristics that directly affect the effectiveness, performance, and safety of the product. On the other hand, CPPs are the process variables that significantly affect CQAs.[24] QbD often uses the statistical tool known as experimental design (DoE) to systematically assess how process factors affect the quality of the end product. It entails setting up experiments to examine alternative CPP combinations inside the designated design space, assessing the outcomes, and figuring out the ideal parameter choices.[25]
- **Risk Assessment and Management:** Throughout the product lifecycle, QbD places a strong emphasis on the identification and management of risks. The identification of possible failure modes and the development of mitigation measures are aided by risk assessment techniques like Failure Mode and Effects Analysis (FMEA). Risk

management measures are implemented to make sure that the product stays within the specified design area despite unforeseen fluctuations and uncertainties.[26]

- **Real-time monitoring and control:** To ensure product quality, QbD encourages ongoing process monitoring and control. Important process characteristics and quality features may be continuously monitored using Process Analytical Technology (PAT) technologies such as online sensors, spectroscopic techniques, and data processing methods. This enables quick intervention and modifications in the event of anomalies.[27]

APPLICATION OF QbD

- **Pharmaceutical Industry QbD Application:** In this industry, QbD has taken on a vital role in ensuring the effectiveness of procedures and the quality of medicines. It makes it possible to comprehend and exert control over key elements influencing the stability, potency, and safety of drugs. Processes including medicine formulation, process development, manufacturing, and the development of analytical methods are all covered by QbD procedures.[28]
- **Food and beverage industry:** QbD ideas are applied in the food and beverage sector to improve product quality, consistency, and safety. To guarantee desirable product features, taste profiles, and shelf life, it helps maximize production conditions, component selection, and packaging. Using QbD techniques makes it simpler to identify and manage important elements that affect the safety and quality of food.[29]
- **Chemical and Petrochemical Industries**: QbD is used in these areas to improve production procedures and guarantee consistent product quality. These sectors produce chemicals and petrochemicals. In order to achieve targeted product standards and reduce variability, it aids in pinpointing important process elements, developing design spaces, and putting into place cutting-edge monitoring and control systems.[30]
- **Other industries:** QbD concepts may be used in other industries, including nanotechnology, biotechnology, medical devices, and cosmetics.[31] These industries use QbD practices to speed up product development, improve product usability, and guarantee regulatory compliance.[32]

QbD IMPLEMENTATION IN THE TABLET MANUFACTURING PROCESS IS AN EXAMPLE OF A CASE STUDY

The pharmaceutical sector has improved the quality and effectiveness of its tablet production processes by effectively integrating QbD concepts.

As an illustration, let's look at the production of a tablet containing a delicate active pharmaceutical ingredient (API).

Identifying Critical Quality Attributes and Critical Process Parameters.
CQAS: Tablet hardness, dissolving rate, content uniformity, and API stability are examples of potential CQAs in this situation.
CPPS: The CPPs may include compression force, drying circumstances, and granulation parameters (such as binder type and concentration, and granulation time).

Design of Experiments (DOE): A DoE approach is used to carefully assess how various process parameters affect the CQAS of the tablet. In the study, tablets are made as the chosen CPPs are modified within the specified design area. The effectiveness of the finished tablets' hardness, dissolution, and homogeneity of content is next evaluated.

Risk assessment and management: During the manufacture of tablets, a risk assessment is carried out to identify probable failure mechanisms and the risks connected with them. In order to decrease the effect of recognized risks on product quality, mitigation methods are created. If moisture absorption during the drying process is thought to be a danger, for instance, suitable steps can be taken, such as changing the drying environment or developing moisture management.

Real-Time Monitoring: Critical process parameters like as moisture content, API concentration, and granule characteristics may be continuously monitored using Process Analytical Technology (PAT) tools like near-infrared (NIR) spectroscopy. Continuous monitoring makes it possible to spot deviations from the essential specifications right away and put the required corrective measures in place to keep the process within the design space. The industry that makes tablets might benefit in several ways from using QbD. Improved product consistency and quality, a more robust process, less variability, and fewer batch failures are a few of these. QbD paves the way for resource optimization, post-approval modification mitigation, and manufacturing process simplification. The manufacturing of high-quality tablets that satisfy legal criteria and patient expectations is ultimately ensured by the use of QbD.

IMPLEMENTING QUALITY BY DESIGN IN A BIOPHARMACEUTICAL MANUFACTURING PROCESS: A CASE STUDY

The successful integration of QbD concepts into a biopharmaceutical production process is examined in this case study. The objectives were to raise product quality, increase the efficiency of procedures, and ensure regulatory compliance.

Background: When developing a complicated biologic, XYZ Biopharma found it difficult to maintain consistent product quality and process effectiveness. Regulators became concerned as more batches were failing as a result of variations in the product's purity, potency, and stability. XYZ Biopharma chose to apply QbD concepts in order to resolve these problems.

QbD Implementation Steps

Choosing Critical Quality Attributes (CQAS) and Critical Process Parameters (CPPs): These are the first steps in implementing Quality by Design. The CQAs were developed after extensive investigation and analysis that took into account elements such as product potency, purity, impurity profiles, and stability. The CPPS was created after a detailed analysis of the production process, which comprised the steps for cell culture, purification, and formulation.[31]

Design of Experiments (DoE) and Process Optimisation: To assess the influence of various CPPs on the identified CQAs, a systematic DoE technique was adopted. Numerous experiments with varied process parameters were produced within the specified design area. To determine the optimal parameter values that resulted in a higher degree of product quality, the experiment data was evaluated.

Risk Assessment and Management: To identify potential failure mechanisms and related hazards throughout the production process, a thorough risk assessment was conducted. To guarantee product quality and patient safety, risk mitigation techniques were devised, including process controls, monitoring systems, and in-process testing.

Real-time monitoring and control: Equipment for Process Analytical Technology (PAT) has been employed to offer important process parameter monitoring in real-time. The product characteristics, impurity profiles, and process variations were tracked using sophisticated analytical techniques including spectroscopy and chromatography. Continuous data analysis makes it possible for quick interventions and revisions, which keeps the process inside the defined design area.[31,32]

RESULT

Significant reductions in batch failures and product variability were achieved as a result of using QbD ideas in the production process at XYZ Biopharma. Manufacturing cycle time reduction has increased, as has process efficiency. Consistent potency, purity, and stability lead to improved product quality. improved critical factor understanding and control to simplify regulatory compliance. minimization of post-approval changes and related expenses.

DISCUSSION

The QbD approach, which emphasizes product and process understanding and process control, is a science- and risk-based approach to pharmaceutical development. The control strategy, which is an essential component of quality by design, specifies the controls required to guarantee that the product satisfies its quality attributes.

CONCLUSION

Quality by Design (QbD) is a methodical approach that has helped raise product quality and process effectiveness in a number of industries, including the pharmaceutical industry. Organizations may streamline their processes and produce high-quality goods by defining critical quality characteristics and process parameters, utilizing the Design of Experiments (DoE), and applying Process Analytical Technology (PAT) for real-time monitoring and control. Implementing QbD has several advantages, including raising consumer knowledge of product features, lowering variability, and accelerating regulatory compliance. Organizations may decrease batch failures, improve process effectiveness, and lessen the need for post-approval adjustments by anticipating potential risks and frequently monitoring crucial metrics. Data management and interdisciplinary cooperation are difficult tasks, but businesses may solve them by making investments in education, technology, and people. Overall, QbD offers a thorough framework for maintaining process effectiveness and product quality, enabling businesses to meet or exceed client expectations, uphold regulatory compliance, and keep up with the competition in the market. Businesses may improve their production processes, produce reliable, consistent products, and ultimately succeed in the competitive business environment of today by putting QbD ideas into action.

REFERENCES

1. Mozafari MR, Nematollahi MH, Esfandyari-Manesh M, Hashemi M, Adibi H, Nokhodchi A, et al. Quality by Design (QbD) in Pharmaceutical Industry: Tools, Challenges, and Opportunities. Journal of Pharmacy & Pharmaceutical Sciences, 2019; 22(1): 42-62.
2. Rathore AS, Winkle H. Quality by Design for Biopharmaceuticals. Nat Biotechnol, Jan, 2009; 27(1): 26-34.
3. Singh S, Bakshi M. Guidance on the conduct of stress tests to determine the inherent stability of drugs. Pharmaceutical Technology, 2010; 34(10): 52–66.
4. Woodcock J. The concept of pharmaceutical quality. American Pharmaceutical Review, Nov., 2004; 7(6): 10-15.
5. Looby M, Ibarra N, Pierce JJ, Buckley K, O'donovan E, Heenan M, et al. Application of quality by design principles to the development and technology transfer of a major process improvement for the manufacture of a recombinant protein. Biotechnology Progress, Nov-Dec, 2011; 27(6): 1718-29.
6. P.K. Vemuri, N Vishal Gupta. AReview on quality by design approach (QBD) for Pharmaceuticals.International Journal Of Drug Development and Research, March 2015; 7(1): 52-60.
7. Q10: Pharmaceutical Quality System. ICH Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2007.
8. Rathore AS, Sharma A, Chilin D. Applying process analytical technology to biotech unit operations. BioPharm Int., Aug. 2006; 19(8): 48–57.
9. Yu LX. Pharmaceutical quality by design: Product and process development, understanding, and control. Pharmaceutical Research, Apr., 2008; 25(4): 781-91.
10. Gupta A, Fuloria NK. A short review on Quality by design: A New Era of Pharmaceutical drug development. Int J Drug Dev & Res., 2012; 4(3): 19-26.
11. Elliott P, Billingham S, Bi J, Zhang H. Quality by design for biopharmaceuticals: a historical review and guide for implementation. Pharmaceutical bioprocessing, Apr., 2013; 1(1): 105- 22.
12. Nadpara NP, Thumar RV, Kalola VN, Patel PB. Quality By Design (QbD): A Complete Review. Int J Pharm Sci Rev Res., Oct., 2012; 17(2): 20-8.
13. US Food and Drug Administration. Guidance for industry: Q8 pharmaceutical development. Rockville, MD; May, 2006.

14. Food and Drug Administration CDER. Guidance for industry, Q6A specifications for new drug substances and products: Chemical substances, 1999.
15. Nally J.D, Bunn G.Good Manufacturing Practice for pharmaceuticals. Taylor & Francis Group, February 5, 2013: 352.
16. Jagtap K, Chaudhari B, Redasani V. Quality by Design (QBD) concept Review in Pharmaceuticals. Asian Journal of Research in Chemistry, 2022; 15(4): 303-7.
17. Food and Drug Administration CDER. Draft guidance for industry and review staff. Target product profile-A strategic development tool, 2007.
18. Lawrence X, Furness M, Raw A, Outlaw W, Nashed K, Ramos N, et al. Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharm Rev., Apr., 2003; 20(4): 531-6.
19. Raw A, Furness M, Gill D, Adams R, Holcombe F, Lawrence X. Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAs). Adv Drug Delivery, Rev., Feb. 23, 2004; 56(3): 397-414.
20. Miller S, Raw A, Lawrence X. FDA perspective on pharmaceutical solid polymorphism. Polymorphism In the Pharmaceutical and Fine Chemical Industry. 2006. Wiley-VCH, New York.
21. Parmar M. QbD relative to ICH Q8, Q9, Q10: The foundation of QbD, 2012; 25-26.
22. Gibson M. Pharmaceutical preformulation and formulation: A practical guide from candidate drug selection to commercial dosage form. CRC Press, Feb. 8, 2013: 560.
23. Tousey M. The granulation process, basic technologies for tablet making. Pharm Tech Tableting and Granulation, 2002.
24. Petrides D, Koulouris A, Lagonikos P. The Role of process simulation in pharmaceutical process development and product commercialization. Pharm Eng, Jan-Feb, 2002; 22(1): 1-8.
25. Ganzer W, Materna J, Wall MM. Current thoughts on critical process parameters (CPP's) and API Syntheses. Pharmaceutical Technology, Jul. 2, 2005; 29(7): 46-66.
26. Menard E. Quality by design in generic drug development, Presentation to FDA Office of Generic Drugs, 2006.
27. Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design:Concepts for ANDAs. AAPS J., Jun., 2008; 10(2): 268-276.
28. Food and Drug Administration CDER. Guidance for industry, PAT- A framework for innovative pharmaceutical development, manufacturing, and quality assurance, 2001.

29. Kandavalli SR, Khan AM, Iqbal A, Jamil M, Abbas S, Laghari RA, et al. Application of sophisticated sensors to advance the monitoring of machining processes: analysis and holistic review. Int J Adv Manuf Technol, Jan., 2023; 125(3-4): 989-1014.
30. Kumar Manik R, Jain D, Joshi A. Effect of Naturopathy and Ayurveda On cystic Fibrosis: Detailed Review Analysis. Journal of Survey in Fisheries Sciences, Mar. 2023; 10(1S): 1-10.
31. Kumar M, Sridharan S, Sawarkar AD, Shakeel A, Anerao P, Mannina G, Sharma P, Pandey A. Current research trends on emerging contaminants pharmaceutical and personal care products (PPCPs): A comprehensive review. Sci Total Environ, Feb. 10, 2023; 859(Pt 1): 160031.
32. Khalaf EM, Abood NA, Atta RZ, Ramírez-Coronel AA, Alazragi R, Parra RMR, Abed OH, Abosaooda M, Jalil AT, Mustafa YF, Narmani A, Farhood B. Recent progressions in biomedical and pharmaceutical applications of chitosan nanoparticles: A comprehensive review. Int J Biol Macromol, Mar. 15, 2023; 231: 123354.